PA-LINESIGHT
18.10.2021 16:02:05 CEST | Business Wire | Press release
IPS-Integrated Project Services, LLC , headquartered in Blue Bell, Pennsylvania and a subsidiary of Alleghany Capital Corporation , today announced that it has acquired Linesight, a multinational consulting firm headquartered in Dublin, Ireland. IPS is a large EPCMV (Engineering, Procurement, Construction Management and Validation) company with over 1,700 staff across 22 offices worldwide. Linesight is a fast-growing professional consultancy services organization providing project controls to data center providers, life sciences companies, commercial real estate, healthcare, hospitality, retail and residential sectors. Linesight has over 900 staff across 24 offices globally.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211018005645/en/
The acquisition is being approached as a future integrated partnership where IPS will leverage Linesight’s experience and expertise in particular in the data center sector and Linesight in turn will leverage IPS’s expertise in the Life Sciences sector. Both organizations will expand their geographic reach, build on their bench strength and extend their service propositions for their target clients globally. Linesight will continue to serve its clients as it always has, but now has the support of a much larger organization behind it.
Dave Goswami, CEO, IPS stated “This is a transformational transaction for both IPS and Linesight and we are excited to embark on a new growth journey together, supported by Alleghany Capital. By leveraging both companies’ strong track records and combining our skills and management horsepower, we expect to make a meaningful positive difference in the industries we serve. Led by Paul Boylan and a strong leadership team, Linesight is a highly sought after company providing consulting services, including cost and project management, project controls, risk, scheduling and procurement services focused on the data center, life sciences, and other industry sectors.
This fits well with IPS’ complementary services which include engineering, construction management and compliance services. We are thrilled at the prospect of working with the Linesight team to provide a more comprehensive and superior suite of services to our respective clients.”
Paul Boylan, CEO, Linesight added, “This is a pivotal point in Linesight’s long and successful business history and will enable us to deliver on our ambitious strategic plans, expand into new geographies to better service our client needs and extend our portfolio offering in our existing and new target markets. Linesight’s skilled teams will continue to provide the same high-quality levels of service to our clients globally and we see enhanced career opportunities for our people in all our regions. I am energized at the potential of this new business partnership and believe that it positions us well to deliver on our ambitious growth aspirations as we look towards 2022 and beyond.”
About IPS-Integrated Project Services
IPS is a global leader in developing innovative business solutions for the biotechnology and pharmaceutical industries. Through operational expertise and industry-leading knowledge, skill and passion, IPS provides consulting, architecture, engineering, construction management, and compliance services that allow clients to create and manufacture life-impacting products around the world. Headquartered in Blue Bell, Pennsylvania in the United States, IPS is one of the fastest-growing companies servicing the life sciences industry with over 1,700 professionals in the United States, Canada, Brazil, the United Kingdom, Ireland, Switzerland, Singapore, China, and India. For more information about IPS, please visit www.ipsdb.com
.
About Linesight
Linesight is a multinational consultancy firm with over 45 years' experience, providing cost, schedule, risk, program and project management services to a multitude of sectors including Data Centers, Life Sciences, Commercial, High-Tech Industrial, Residential, Hospitality, Healthcare and Retail. Linesight’s specialist project teams, each with specific skills and experience, provide better predictability of project outcomes, faster project delivery, greater cost efficiency and maximum value for money for its clients. For further information, please visit http://www.linesight.com
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211018005645/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FPT Named an OpenAI Select Partner6.8.2026 02:00:00 CEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release
Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release
Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 16:00:00 CEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom